Reyvow (lasmiditan) / Ildong, Eli Lilly, Daiichi Sankyo, Organon - LARVOL DELTA

Drugs for acute treatment of migraine. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain

The Remote Electrical Neuromodulation (REN) wearable reduces medication use for the treatment of chronic pain in migraine patients (PAINWeek 2026) - "Medication types included three categories that were presented to patients using commercial drug names: (1) over-the-counter (OTC; e.g. Advil, Excedrin, Tylenol), (2) first-line prescribed medications including oral triptans (e.g. Imitrex, Maxalt, Relpax) and oral medication for nausea (e.g. Zofran, Reglan, Compazine), (3) second-line prescribed medications including nasal/injectable triptans (e.g. Tosymara, Onzetra, Zembrace, Zoming) and branded new generation medications (Reyvow, Nurtec, and Ubrelvy). Data from 31,516 migraine patients who conducted 148,705 REN treatments were analyzed. Treatment-level analysis showed that 71.1% of the treatments were performed without the use of any prescribed medications (50.6% REN alone, 14.4% REN + OTC meds), while 28.9% were conducted in conjunction with first- or second-line prescribed medications. A patient-level analysis looked at a subset of 2,653 patients who performed at least 10 REN treatments each, in which they reported..."

Clinical • CNS Disorders • Migraine • Pain

Efficacy and cardiovascular safety of lasmiditan in patients with cardiovascular risk factors: A systematic review and meta-analysis with updated synthesis of triptan safety data. (PubMed, Headache) - "Lasmiditan demonstrated efficacy and favorable CV safety in CV-risk populations, with no vasoconstrictive events detected across 5126 participants. Common central nervous system adverse effects, particularly dizziness, require careful patient counseling. The recent voluntary market withdrawal of lasmiditan underscores the need for continued development and evaluation of non-vasoconstrictive acute migraine treatments for patients with CV contraindications to triptans."

Journal • Retrospective data • Review • Cardiovascular • CNS Disorders • Migraine • Pain

Innovation is not enough: lessons from lasmiditan for real-world effectiveness in acute migraine therapy. (PubMed, Expert Rev Neurother) - No abstract available

Journal • Real-world evidence • CNS Disorders • Migraine • Pain

Regulation of mitochondrial biogenesis by the 5-HT1F receptor and its agonist in inferior spinal cords after spinal cord injury. (PubMed, Neurosci Lett) - "Activation of the 5-HT1FR promotes MB in spinal cord tissue below the injury level after SCI. This mechanism may contribute to its therapeutic potential for secondary spasticity."

Journal • CNS Disorders • Movement Disorders • Muscle Spasticity • Orthopedics • NRF1 • TFAM

Lasmiditan Efficacy and Cardiovascular Safety in High-Risk Patients: A Systematic Review and Meta-Analysis (EAN 2026) - "Lasmiditan demonstrates robust efficacy and favorable cardiovascular safety with complete absence of vasoconstriction events. Given tolerability profiles, gepants may represent preferred first-line cardiovascular-safe alternatives, with lasmiditan reserved for gepant non-responders."

Retrospective data • Review • Cardiovascular • CNS Disorders • Migraine

Ildong Pharmaceutical’s domestically supplied new migraine drug ’Reyvow (lasmiditan)’ will end sales in Korea at the end of this year (Chosun Biz) - "Ildong Pharmaceutical said it was recently notified by original developer Eli Lilly and Company of a decision to halt global production and supply of Reyvow. The company noted the decision was a business strategy based on changes in the global migraine treatment landscape and the expansion of alternative therapies, not due to safety or quality issues. Reyvow was developed as an acute migraine treatment....Entering the domestic market without coverage meant patients had to pay the full price, which may have acted as a constraint on prescription expansion."

Commercial • Migraine • Pain

A retrospective cohort study comparing treatment persistence between rimegepant and lasmiditan for the acute treatment of migraine in the US. (PubMed, Cephalalgia) - "A significantly higher proportion of individuals in the rimegepant cohort were treatment persistent compared with the lasmiditan cohort (OR 3.79 [95% CI 3.23-4.41]). This finding remained consistent across lasmiditan dosages (50 mg: 5.05 [3.87-6.60]; 100 mg: 3.33 [2.78-4.00]), chronic migraine diagnosis (3.89 [3.21-4.71]), or PRUCS (ORs ranged from 2.78 to 4.63; all statistically significant).ConclusionRimegepant users demonstrated higher treatment persistence over 12 months compared to lasmiditan users, which could reflect better real-world treatment satisfaction."

Clinical • Journal • Retrospective data • CNS Disorders • Migraine • Pain

The impact of ubrogepant on the use of other migraine acute treatments, opioid discontinuation, and healthcare utilization: Results from a pre-post opioid subcohort analysis (AHS 2026) - "Acute medications other than ubrogepant included acetaminophen, almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan, dihydroergotamine, ergotamine, amobarbital, aprobarbital, butabarbital, butalbital, mephobarbital, metharbital, pentobarbital, phenobarbital, secobarbital, talbutal, barbital, codeine, hydrocodone, meperidine, morphine, oxycodone, propoxyphene, tramadol, aspirin, bromfenac, celecoxib, diclofenac, diflunisal, esomeprazole, etodolac, famotidine, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, sulindac, tolmetin, lasmiditan, Zavegepant, and Rimegepant (<15 pills). Opioid use included acetaminophen/tramadol, oxymorphone, levorphanol, buprenorphine/naloxone, meperidine, morphine, oxycodone, codeine, methadone, oxycodone, hydromorphone, butorphanol, and tapentadol... In patients with a history of opioid use,..."

HEOR • CNS Disorders • Migraine • Pain

Real-World Safety and Effectiveness of Lasmiditan in Patients with Migraine: A Post-Marketing Observational Study in Japan. (PubMed, Neurol Ther) - "Lasmiditan was associated with a manageable safety profile and effectiveness in patients with acute migraine in routine clinical practice in Japan, with no new safety concerns identified."

Journal • Observational data • P4 data • Real-world evidence • CNS Disorders • Migraine • Pain

Observational study on the usefulness of lasmiditan in migraine patients (JSNE 2026) - No abstract available

Clinical • Observational data • CNS Disorders • Migraine • Pain

Analytical quality by design (AQbD)-assisted bioanalytical method for the estimation of Lasmiditan in human plasma by reverse phase-high performance liquid chromatography (RP-HPLC). (PubMed, J Chromatogr Sci) - "Bio analysis employing protein precipitation was performed to extract Lasmiditan from human plasma using Dolutegravir as the internal standard. Furthermore, the method was evaluated using the Whiteness Assessment Tool (Blue Applicability Grade Index), yielding a high score of 82.5, indicating superior performance in terms of analytical efficiency, environmental friendliness and operator safety. Thus, the developed method can be applied for estimation of preclinical and clinical samples of Lasmiditan with improved accuracy and precision."

Journal • CNS Disorders • Migraine • Pain

From structural evolution to an AI-driven future of 5-HT1F receptor agonists for migraine therapy. (PubMed, Eur J Med Chem) - "The clinical approval of lasmiditan has validated the therapeutic potential of 5-HT1F agonism, although its association with central nervous system adverse effects underscores the need for safer and more selective ligands...We further discuss how artificial intelligence (AI)-driven approaches, including structure-aware generative modeling and knowledge-guided design, offer a strategic pathway to address the ligand-scarcity challenge of this low-data GPCR, potentially accelerating the discovery of next-generation 5-HT1F receptor agonists with optimized safety and efficacy. Collectively, this work links biological insight, medicinal chemistry evolution, and emerging computational tools to inform the development of improved antimigraine therapies."

Journal • Review • CNS Disorders • Migraine • Pain

PIONEER-PEDS2: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (clinicaltrials.gov) - P3 | N=566 | Terminated | Sponsor: Eli Lilly and Company | N=1000 ➔ 566 | Trial completion date: Jan 2028 ➔ Dec 2025 | Recruiting ➔ Terminated | Trial primary completion date: Jan 2028 ➔ Dec 2025; Study terminated due to strategic business decision

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • CNS Disorders • Migraine • Pain • Pediatrics

PIONEER-PEDS1: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (clinicaltrials.gov) - P3 | N=851 | Terminated | Sponsor: Eli Lilly and Company | N=1633 ➔ 851 | Trial completion date: Nov 2026 ➔ Nov 2025 | Recruiting ➔ Terminated | Trial primary completion date: Nov 2026 ➔ Nov 2025; Study terminated due to strategic business decision

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • CNS Disorders • Migraine • Pain • Pediatrics

Structural basis of LY334370 recognition and selectivity at the 5-HT1F receptor. (PubMed, Biochem Biophys Res Commun) - "Furthermore, comparative analysis with the lasmiditan-bound 5-HT1FR-Gαi1 complex reveals distinct agonist binding modes and provides mechanistic insight into Gαi/o subtype-specific coupling. Collectively, these findings elucidate the structural basis of 5-HT1FR activation, ligand selectivity, and G protein coupling, providing a structural framework for the rational design of safer and more effective anti-migraine drugs."

Journal • CNS Disorders • Migraine • Pain

Ditan Acute tReatments: Effectiveness and Tolerability (DART) (clinicaltrials.gov) - P=N/A | N=100 | Completed | Sponsor: University of Florence | Recruiting ➔ Completed | Trial completion date: Jun 2024 ➔ Dec 2025

Trial completion • Trial completion date • CNS Disorders • Migraine • Pain

Cost of rimegepant and lasmiditan associated adverse events, for acute treatment in migraine in Spain. (PubMed, Expert Rev Pharmacoecon Outcomes Res) - "The probability of RIM saving in all analysis was 100%. In accordance with this model, the favorable safety profile of RIM compared to LAS would generate savings for the SNHS in health-care resources in all the scenarios considered."

Adverse events • Journal • CNS Disorders • Migraine • Pain

The implications of losing treatment options: Why lasmiditan's discontinuation matters. (PubMed, Headache) - No abstract available

Journal • CNS Disorders • Migraine • Pain

New trends in migraine management: Transcending the traditional divide between acute and preventive treatments (EHF-EHC 2025) - "Acute medications like lasmiditan and rimegepant not only relieve symptoms quickly but also lower attack frequency and disease impact over time. Clinicians should understand that acute and preventive treatments are linked goals to improve management and prevent progression. Personalized plans are needed to enhance both treatments and lessen the overall impact on patients."

CNS Disorders • Migraine • Pain

Lasmiditan-overuse headache?: Time-series clustering analysis for treatment pattern of lasmiditan for two years from the initial prescription (EHF-EHC 2025) - "According to real-world data, there are three prescription patterns. There might be a possibility of lasmiditan overuse. The appropriate use of lasmiditan should continue to be investigated."

Cardiovascular • CNS Disorders • Migraine • Pain

Investigation of the relationship between weather and headache attacks: Smartphone application data analyzed with artificial intelligence (EHF-EHC 2025) - " Using data from January to December 2023, we selected users who had used triptans or lasmiditan at least once and recorded headaches on 1–14 days per month, identifying them as having episodic migraine... This real-world big data analysis demonstrated that several weather conditions— including rain, sunshine, wind, and falling barometric pressure—are significantly related to hourly headache occurrence. Fig. 1"

CNS Disorders • Migraine • Pain

Effectiveness and tolerability of lasmiditan in the acute treatment of migraine: a real-world, prospective, multicentric study (DART study). (PubMed, Ther Adv Neurol Disord) - P | "Lasmiditan effectiveness was not associated with the previous triptan failure and may therefore represent a valuable therapeutic option in subjects who did not benefit from, or have contraindications to, triptans. The study was preregistered on clinicaltrial.gov, NCT05903040 (https://clinicaltrials.gov/study/NCT05903040?cond=migraine&intr=lasmiditan&rank=5)."

Clinical • Journal • Real-world evidence • CNS Disorders • Migraine • Mood Disorders • Pain • Psychiatry

Loss of HTR1F Expression Increases Mortality and Prevents Lasmiditan-Induced Kidney Recovery After Moderate to Severe AKI in Mice (KIDNEY WEEK 2025) - "Both WT-Purchased and HTR1F Fl/Fl Las-treated mice exhibited a ~20% reduction in SCr 7d post I/R-AKI compared to vehicle-treated controls, an effect not observed in EIIa-Cre/HTR1F Fl/Fl mice. Conclusion These data underscore the importance of HTR1F expression and agonism in renal repair and recovery, and further highlight the repurposing potential of lasmiditan for the treatment of AKI and/or KD onset/progression."

Preclinical • Acute Kidney Injury • Cardiovascular • Fibrosis • Immunology • Metabolic Disorders • Nephrology • Renal Disease • Reperfusion Injury

Lasmiditan ameliorates cortico-hippocampal pathology and improves cognition in aging parkinsonian mice. (PubMed, Exp Neurol) - "In older (10-11.5 months old) mice, although the effects were milder, daily lasmiditan administration increased MB and bettered cognitive abilities. In essence, these findings indicate that repurposing lasmiditan could be a potential strategy to address PD-related cognitive decline."

Journal • Preclinical • CNS Disorders • Cognitive Disorders • Metabolic Disorders • Mood Disorders • Movement Disorders • Parkinson's Disease • Psychiatry • THY1